Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian CancerSetsuko K. Chambers, David S. Alberts, Amanda F. Baker et al.|Clinical Cancer Research|2010Cited by 55